ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LCTX Lineage Cell Therapeutics Inc

1.49
0.09 (6.43%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,177,094
Bid Price
Ask Price
News -
Day High 1.61

Low
0.8414

52 Week Range

High
1.61

Day Low 1.33
Company Name Stock Ticker Symbol Market Type
Lineage Cell Therapeutics Inc LCTX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.09 6.43% 1.49 19:50:10
Open Price Low Price High Price Close Price Prev Close
1.37 1.33 1.61 1.48 1.40
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,905 4,177,094 $ 1.48 $ 6,162,727 - 0.8414 - 1.61
Last Trade Time Type Quantity Stock Price Currency
20:00:00 98,313 $ 1.48 USD

Lineage Cell Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
277.14M 188.53M - 8.95M -21.49M -0.11 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Lineage Cell Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LCTX Message Board. Create One! See More Posts on LCTX Message Board See More Message Board Posts

Historical LCTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.211.611.211.34860,1980.2823.14%
1 Month1.061.611.03011.25867,3100.4340.57%
3 Months1.201.610.84141.14791,0100.2924.17%
6 Months1.201.610.84141.12645,9530.2924.17%
1 Year1.401.610.84141.24603,6950.096.43%
3 Years2.303.000.84141.80699,620-0.81-35.22%
5 Years0.95953.13160.53391.64815,4120.530555.29%

Lineage Cell Therapeutics Description

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Your Recent History

Delayed Upgrade Clock